A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

D. L. Ahmann; D. J. Schaid; J. N. Ingle; H. F. Bisel; A. J. Schutt; J. C. Buckner; H. J. Long; J. Rubin

doi:10.1097/00000421-199106000-00001

A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

D. L. Ahmann, D. J. Schaid, J. N. Ingle, H. F. Bisel, A. J. Schutt, J. C. Buckner, H. J. Long, J. Rubin

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

Original language	English (US)
Pages (from-to)	179-183
Number of pages	5
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	14
Issue number	3
DOIs	https://doi.org/10.1097/00000421-199106000-00001
State	Published - 1991

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-199106000-00001

Cite this

Ahmann, D. L., Schaid, D. J., Ingle, J. N., Bisel, H. F., Schutt, A. J., Buckner, J. C., Long, H. J., & Rubin, J. (1991). A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 14(3), 179-183. https://doi.org/10.1097/00000421-199106000-00001

A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. / Ahmann, D. L.; Schaid, D. J.; Ingle, J. N. et al.
In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 14, No. 3, 1991, p. 179-183.

Research output: Contribution to journal › Article › peer-review

Ahmann, DL, Schaid, DJ, Ingle, JN, Bisel, HF, Schutt, AJ, Buckner, JC, Long, HJ & Rubin, J 1991, 'A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 14, no. 3, pp. 179-183. https://doi.org/10.1097/00000421-199106000-00001

@article{af674092e2ba487bbec5e0d6d1b7fbe4,

title = "A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer",

abstract = "Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.",

author = "Ahmann, {D. L.} and Schaid, {D. J.} and Ingle, {J. N.} and Bisel, {H. F.} and Schutt, {A. J.} and Buckner, {J. C.} and Long, {H. J.} and J. Rubin",

year = "1991",

doi = "10.1097/00000421-199106000-00001",

language = "English (US)",

volume = "14",

pages = "179--183",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

AU - Ahmann, D. L.

AU - Schaid, D. J.

AU - Ingle, J. N.

AU - Bisel, H. F.

AU - Schutt, A. J.

AU - Buckner, J. C.

AU - Long, H. J.

AU - Rubin, J.

PY - 1991

Y1 - 1991

N2 - Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

AB - Ninety-four patients were entered in a clinical trial assessing the clinical activity of cyclophosphamide, doxorubicin, and prednisone (CAP) versus a combination of cyclophosphamide, 5-Flurouracil, and prednisone (CFP) in patients with advanced breast cancer. Objective response rates were comparable, 49% for CFP and 46% for CAP. There was no statistical difference between the duration of response of the two regimens or in time to progression. Most importantly, survival differences were not apparent. Both regimens were clinically tolerable and toxicities, for the most part, were comparable. Thus, no therapeutic advantage existed for either of these polychemotherapy regimens in patients with advanced breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0025916094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025916094&partnerID=8YFLogxK

U2 - 10.1097/00000421-199106000-00001

DO - 10.1097/00000421-199106000-00001

M3 - Article

C2 - 2031502

AN - SCOPUS:0025916094

SN - 0277-3732

VL - 14

SP - 179

EP - 183

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 3

ER -

A randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this